204 related articles for article (PubMed ID: 24641308)
1. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
Gorkom BL; Holme PA; Joch C; Rogosch T; Feussner A; McKeand W; Roberts J; van Heerde W
Hematology; 2020 Dec; 25(1):17-25. PubMed ID: 31852380
[No Abstract] [Full Text] [Related]
3. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.
Golor G; Bensen-Kennedy D; Haffner S; Easton R; Jung K; Moises T; Lawo JP; Joch C; Veldman A
J Thromb Haemost; 2013 Nov; 11(11):1977-85. PubMed ID: 24112951
[TBL] [Abstract][Full Text] [Related]
4. Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S9-S12. PubMed ID: 27288065
[TBL] [Abstract][Full Text] [Related]
5. Recombinant fusion protein linking factor VIIa with albumin (rVIIa-FP): Tissue distribution in rats.
Herzog E; Harris S; McEwen A; Henson C; Pragst I; Dickneite G; Schulte S; Zollner S
Thromb Res; 2014 Aug; 134(2):495-502. PubMed ID: 24958222
[TBL] [Abstract][Full Text] [Related]
6. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.
Schulte S
Thromb Res; 2008; 122 Suppl 4():S14-9. PubMed ID: 18929521
[TBL] [Abstract][Full Text] [Related]
7. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Metzner HJ; Pipe SW; Weimer T; Schulte S
Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
[TBL] [Abstract][Full Text] [Related]
8. Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
Weimer T; Wormsbächer W; Kronthaler U; Lang W; Liebing U; Schulte S
Thromb Haemost; 2008 Apr; 99(4):659-67. PubMed ID: 18392323
[TBL] [Abstract][Full Text] [Related]
9. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
10. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
11. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.
Salas J; Liu T; Lu Q; Kulman JD; Ashworth T; Kistanova E; Moore N; Pierce GF; Jiang H; Peters R
Thromb Res; 2015 May; 135(5):970-6. PubMed ID: 25721936
[TBL] [Abstract][Full Text] [Related]
13. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
Shirahata A; Kamiya T; Takamatsu J; Kojima T; Fukutake K; Arai M; Hanabusa H; Tagami H; Yoshioka A; Shima GM; Naka GH; Fujita GS; Minamoto Y; Kamizono J; Saito H
Int J Hematol; 2001 Jun; 73(4):517-25. PubMed ID: 11503968
[TBL] [Abstract][Full Text] [Related]
17. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa does not induce hypercoagulability in vitro.
Gallistl S; Cvirn G; Muntean W
Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
20. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.
Mauser-Bunschoten EP; de Goede-Bolder A; Wielenga JJ; Levi M; Peerlinck K
Neth J Med; 1998 Dec; 53(6):249-55. PubMed ID: 9883002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
